Search

Displaying results 2631 - 2640 of 10000 in total
  1. Drug

    MK-8245

    go.drugbank.com/drugs/DB13024
    Investigational

    MK-8245 has been used in trials studying the treatment of Type 2 Diabetes Mellitus.

    Categories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Tyrothricin

    go.drugbank.com/drugs/DB13503
    ApprovedWithdrawn

    and 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022]. … This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors)

    Mixtures: Dorithricin Halstabletten Classic 0,5 mg / 1,0 mg / 1,5 mg Lutschtabletten, Dorithricin Halstabletten Waldbeergeschmack 0,5 mg / 1,0 mg / 1,5 mg Lutschtabletten
  3. Drug

    GC012F

    go.drugbank.com/drugs/DB22406
    Investigational

    GC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).

  4. Drug

    MK-7145

    go.drugbank.com/drugs/DB11968
    Investigational

    MK-7145 has been used in trials studying the treatment of Hypertension and Renal Insufficiency.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  5. Drug

    Ox bile extract

    go.drugbank.com/drugs/DB14016
    Approved

    Mixtures: İNTESTİNOL 59,4 MG/21,3 MG/71,1 MG KAPLI TABLET, 120 ADET, İNTESTİNOL 59,4 MG/21,3 MG/71,1 MG KAPLI TABLET, 60 ADETSynonyms: Ox bile, Ox bile extract
  6. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell. … Sipavibart is a recombinant human IgG1 monoclonal antibody that is long-acting.

    Synonyms: Immunoglobulin G1 [242-phenylalanine,243-glutamic acid,260-tyrosine,262-threonine,264-glutamic acid,339-serine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding, 1-chain), disulf
  8. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … It targets aldosterone excess, a primary underlying driver of treatment resistance and organ damage in cardiovascular diseases [A275512, A275515].

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: (+)-(r)-n-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide, N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamide
  9. Drug

    Adrulipase alfa

    go.drugbank.com/drugs/DB15004
    Investigational

    MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).

  10. Drug

    Abrilumab

    go.drugbank.com/drugs/DB15076
    Investigational

    Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).